Flecainide Sandoz 50mg 30 tablets — Made in Germany — Free Delivery

AV nodal persistent tachycardia; arrhythmias associated with Wolff-Parkinson-White syndrome and similar disorders due to the presence of additional pathways - in case of failure of other types of treatment.

Symptomatic paroxysmal ventricular arrhythmia of high severity, life-threatening patient, in the absence of response to other types of therapy. It is also used for intolerance or impossibility of other forms of therapy.

Paroxysmal atrial fibrillation (atrial fibrillation, atrial flutter, atrial tachycardia) in patients with adverse symptoms after conversion, provided there is an undoubted need for therapy, is confirmed by the severity of clinical symptoms, if other treatments are ineffective.

Before starting the use, the presence of heart diseases of organic origin and / or violations of the left ventricular ejection fraction should be excluded, since in this case there is a risk of an undesirable increase in arrhythmia.

- Hypersensitivity reaction to flecainide or any of the excipients of the preparation.

- heart failure, a history of myocardial infarction, with asymptomatic ventricular ectopia or asymptomatic non-sustained ventricular tachycardia.

- cardiogenic shock.

- Long-term atrial fibrillation, in the therapy of which no attempt was made to convert sinus rhythm, as well as valvular heart disease with significant hemodynamic disturbances.

- Decreased or impaired ventricular function, in the presence of cardiogenic shock, high severity bradycardia (less than 50 beats per minute), high severity hypotension.

- Use in combination with Class I antiarrhythmic preparations  (sodium channel blockers).

- Brugada syndrome.

- in the absence of the possibility of pacing, flecainide should not be used in the treatment of patients with dysfunction of the sinus node, impaired atrial conduction, with atrioventricular blockade of the second or higher degree, with bundle branch block or distal blockade.

- Asymptomatic ventricular arrhythmia or mild symptoms of ventricular arrhythmia.

active substance: flecainide acetate;

1 tablet contains flecainide acetate 50 mg or 100 mg

corn starch, microcrystalline cellulose, corn starch, croscarmellose sodium, magnesium stearate.

The preparation  is used orally. To eliminate the effect of food on the absorption of the preparation  substance, Flecainide Sandoz ® should be taken on an empty stomach or one hour before meals. Flecainide Sandoz ® 100 mg tablet can be divided into two equal parts.

The initiation of therapy with flecainide acetate and changes in the dosage regimen should be carried out under control with ECG monitoring and control of the concentration of the substance in the blood plasma. Some patients currently require hospitalization, particularly those with life-threatening ventricular arrhythmias. The decision on the need for hospitalization is made by a specialist. In patients with organic heart disease, especially those with a history of myocardial infarction, therapy with flecainide should only be started if other antiarrhythmic preparations, with the exception of preparations  of the IS class (especially amiodarone), are ineffective or intolerable, and under the condition that non-preparation  treatment (surgery, amputation, implantation of a defibrillator) is not indicated. During the period of therapy, constant ECG monitoring and control of the concentration of the substance in the blood plasma is necessary.

Children.

Flecainide Sandoz ® is not recommended for use in the treatment of children under the age of 13 due to the presence of adequate safety and efficacy data.